Icon
+91 94997 68112
Login Register

Iclusig - (15, 45 mg; Tablet)

Ponatinib Takeda
15, 45 mg; Tablet
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
Less Than 5
 None
Iclusig is a kinase inhibitor indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy (1). This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with Iclusig.
Yes
****** **** ****** (******) ** ****** '*** ** **** **, ****. **** *** **** *** ****** ************ ** *** ****. ** ***** **** ******'* ********* ****** **** **** **** *** ****** **** ***** * **** *** ** ******* '*** *** '***.
Iclusig Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6
****** **** *** **** *** ******* ******* (***** ******) ******* (***** ******) ******* (***** ******)
**** **** *** **** *** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, ****
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** ***\ ********* *** **, **** ******* ******** ******* *** **** *** *** ****
**** ** \ ** *** **, **** ******* ********* ******** ***** *** ****
  1. *** **, **** : * ****-** ** ***** *** ***** ** *** *** *******.
  2. *** **, **** : ****** **** ****** ** ****** ** '***.
  3. *** **, **** : ****** ***** ** ******* *********, ***** ****** **** ************ ** ******* '*** *** '*** ** ****.
  4. *** **, **** : ****** **** ****** **** ***** ****** ****** '***
  5. *** **, **** : **** ******** ****** ** *** **** ** ****** **** ******* '***, '***, '*** *** '***
  6. *** **, **** : ****** **** **** **** ************ ** ******* '***, '***, '*** *** '***
  7. *** *, **** : ****** *** ****** ******* ********** ** ******* *****.

Iclusig - (10, 30 mg; Tablet)

Ponatinib Takeda
10, 30 mg; Tablet
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
Iclusig is a kinase inhibitor indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy
Yes
**** *** **** *** ****** ************ ** *** ****. ** ***** **** *** ********* ****** **** **** *** ***** * **** *** ** ******* '*** *** '***.
Iclusig Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6
**** **** *** **** *** ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ ********* *** **, **** ******* ********* ******** ******* *** **** *** *** ****
  1. *** **, **** : * ****-** ** ***** *** ***** ** *** *** *******.
  2. *** **, **** : ****** **** **** **** ************ ** ******* '***, '***, '***, *** '*** *** ******** ** *** **, ****
  3. *** **, **** : ****** ******** ********* ******** *** *** *** ********* *** ***** *********. ** *** ***** ************.
  4. *** **, **** : ****** *** **** ******* ********** ** ******* *****.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.